ReviewRSC advances2026
Assembling peptides for treating Alzheimer's disease: a supramolecular perspective.
Review in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is a progressive neurodegenerative disorder. Current clinical treatments for AD primarily focus on alleviating symptoms but still face limitations such as suboptimal efficacy, side effects, and irreversible neuronal loss. Misfolding of the Aβ peptide plays a key role in AD pathogenesis and progression. By targeting this AD pathology, peptide-based therapeutics, particularly peptide assembly strategies, hold immense potential in AD therapy. Unlike sequence-based conventional reviews, this review reorganizes relevant advances from the perspective of a unified supramolecular framework. We first illustrate the structural, kinetic, and thermodynamic molecular basis of the pathological Aβ assembly and its neurotoxicity. Three mainstream supramolecular intervention strategies are then discussed: peptides redirecting the regulation of aberrant Aβ assembly, neuroprotective peptide scaffolds, and drug-loading peptide hydrogels. Finally, a universal rational design workflow for multifunctional peptide therapeutics is summarized, and perspectives on advanced directions are outlined.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.